BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/2/2021 12:29:13 PM | Browse: 411 | Download: 776
 |
Received |
|
2020-12-12 15:47 |
|
Peer-Review Started |
|
2020-12-12 15:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-12-18 13:07 |
|
Revised |
|
2021-01-01 04:45 |
|
Second Decision |
|
2021-02-22 13:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-02-22 19:44 |
|
Articles in Press |
|
2021-02-22 19:44 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-03-01 14:16 |
|
Typeset the Manuscript |
|
2021-03-29 12:58 |
|
Publish the Manuscript Online |
|
2021-04-02 12:29 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
An-Che Cheng, Yi-Jia Lin, Sung-Hua Chiu and Yu-Lueng Shih |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yu-Lueng Shih, PhD, Academic Research, Associate Professor, Attending Doctor, Department of Internal Medicine, Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, No 325, Section 2, Cheng-Kung Road, Neihu, Taipei 114, Taiwan. albreb@ms28.hinet.net |
| Key Words |
Metastatic melanoma with unknown primary; Liver metastasis; Immune checkpoint inhibitor; Programmed death protein-1; Cytotoxic T-lymphocyte-associated antigen 4; Case report |
| Core Tip |
Hepatic metastatic melanoma with an unknown primary site (MUP) is extremely rare and there is limited information on the pathogenesis, clinical and imaging features, pathological findings and treatment outcome. There are no guidelines for the use of immune checkpoint inhibitors (ICIs) in hepatic MUP. We report the first case of hepatic MUP treated by ICIs with combined cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death protein-1 (PD-1), describing the clinical features, imaging, pathological findings, and outcome. This case showed better treatment outcome than previous cases of hepatic MUP. ICIs combined with PD-1 and CTLA-4 may be considered as the first‐line therapy for patients with hepatic MUP. |
| Publish Date |
2021-04-02 12:29 |
| Citation |
Cheng AC, Lin YJ, Chiu SH, Shih YL. Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report. World J Clin Cases 2021; 9(11): 2641-2648 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i11/2641.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i11.2641 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
